<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30972" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Varenicline</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Dharminder</given-names>
          </name>
          <aff>Kaweah Delta Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dharminder Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30972.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Varenicline&#x000a0;is a medication prescribed to&#x000a0;help patients stop&#x000a0;smoking, targeting one of the most modifiable risk factors for preventing human disease. With smoking contributing to over 400,000 premature deaths annually in the United States, varenicline&#x000a0;helps reduce morbidity and mortality linked to conditions such as atherosclerosis, coronary artery disease, cerebrovascular disease, and malignancies.&#x000a0;Additionally, nasal varenicline was recently approved for patients with dry eye disease. Understanding the indications, mechanism of action, administration methods, adverse effects, contraindications, toxicity, and monitoring of varenicline is essential for healthcare professionals. This knowledge enables informed decision-making in prescribing and optimizing dosage regimens, ultimately improving patient outcomes&#x000a0;associated with smoking cessation and other therapeutic areas.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the mechanism of action of varenicline.</p></list-item><list-item><p>Determine&#x000a0;the potential adverse&#x000a0;drug reactions associated with varenicline therapy.</p></list-item><list-item><p>Identify the appropriate dosing schedule for patients receiving varenicline.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from varenicline therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30972&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30972">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30972.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Smoking is&#x000a0;one of the most significant contributors to&#x000a0;morbidity and mortality and one of the most modifiable risk factors for preventing human disease. More than 400,000&#x000a0;Americans die prematurely every year from conditions associated with&#x000a0;tobacco use; this accounts for 1 of every 5 deaths in the U.S. annually.&#x000a0;The major diseases caused by cigarette smoking include premature atherosclerosis, coronary artery disease, cerebrovascular disease, aortic aneurysms, chronic airway obstruction, malignancies, and sudden infant death syndrome.&#x000a0;Smoking is a preventable risk factor that clinicians can&#x000a0;treat through counseling and pharmacotherapy to&#x000a0;reduce the burden of disease impacting the population of the United States and the world.</p>
        <p>Nicotine is the principal constituent of tobacco and is&#x000a0;the primary cause&#x000a0;of the associated addictive behavior.<xref ref-type="bibr" rid="article-30972.r1">[1]</xref>&#x000a0;A comprehensive approach to education, including cessation advice, pharmacologic assistance, and counseling, can increase the likelihood of smoking cessation success almost 3-fold. Various&#x000a0;first-line&#x000a0;agents have been used to aid in smoking cessation, including nicotine replacement therapy and bupropion. However, they have minimal long-term efficacy.<xref ref-type="bibr" rid="article-30972.r2">[2]</xref>&#x000a0;Varenicline is one of the more recently introduced medications on the market.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>Smoking cessation:</bold>&#x000a0;Varenicline received FDA approval&#x000a0;in May of 2006. This medication is&#x000a0;preferred for patients who intend to stop smoking&#x000a0;due to its effectiveness in preventing both short-term and long-term relapse. Varenicline is superior to bupropion and has equal efficacy to nicotine replacement therapy.<xref ref-type="bibr" rid="article-30972.r3">[3]</xref><xref ref-type="bibr" rid="article-30972.r4">[4]</xref><xref ref-type="bibr" rid="article-30972.r5">[5]</xref>&#x000a0;Due to its partial agonist properties, varenicline also has a lower&#x000a0;risk of withdrawal symptoms&#x000a0;compared to other drugs prescribed for smoking cessation. The American Heart Association/American Stroke Association (AHA/ASA) suggests that initiating varenicline to promote smoking cessation should be considered for patients hospitalized with acute ischemic stroke.<xref ref-type="bibr" rid="article-30972.r6">[6]</xref></p>
        <p>The American Thoracic Society (ATS) suggests the following approaches for treating tobacco dependence:</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients who are tobacco-dependent and initiating treatment, the ATS recommends varenicline over a nicotine patch.</p>
          </list-item>
          <list-item>
            <p>The ATS suggests using varenicline over bupropion for patients who are tobacco-dependent&#x000a0;and initiating treatment.</p>
          </list-item>
          <list-item>
            <p>The ATS recommends varenicline combined with a nicotine patch over varenicline alone for patients who are tobacco-dependent&#x000a0;and initiating treatment.</p>
          </list-item>
          <list-item>
            <p>The ATS recommends prioritizing varenicline over electronic cigarettes for patients who are tobacco-dependent&#x000a0;and&#x000a0;initiating treatment. Notably, the strength of this recommendation is influenced by the emerging evidence of serious adverse effects associated with electronic cigarette use. Continued reporting of these adverse effects may necessitate a reassessment of the strength of this recommendation. Furthermore, this guidance pertains specifically to the supervised treatment of tobacco dependence and should not be generalized to unsupervised treatment or recreational use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For patients who are&#x000a0;tobacco-dependent&#x000a0;and&#x000a0;are not prepared to discontinue tobacco use, the ATS recommends that clinicians initiate treatment with varenicline instead of waiting until patients are ready to stop tobacco use.<xref ref-type="bibr" rid="article-30972.r7">[7]</xref></p>
          </list-item>
        </list>
        <p><bold>Dry eye:</bold>&#x000a0;Varenicline nasal spray is now FDA-approved for the symptomatic management of dry eye disease.<xref ref-type="bibr" rid="article-30972.r8">[8]</xref><xref ref-type="bibr" rid="article-30972.r9">[9]</xref></p>
      </sec>
      <sec id="article-30972.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The components of the midbrain that play a pivotal role in drug reinforcement, motility, and associative motor learning include the ventral tegmental area and substantia nigra pars compacta.<xref ref-type="bibr" rid="article-30972.r10">[10]</xref>&#x000a0;Increasing dopamine release from ventral tegmental area neurons targeting&#x000a0;the nucleus accumbens contributes to the pathophysiology of addiction. Nicotine acts on dopaminergic receptors in the ventral tegmental area, causing a burst firing of dopamine neurons, leading to drug reinforcement.</p>
        <p>Varenicline&#x000a0;acts as a partial nicotine receptor agonist similar to cytisine.</p>
        <p>According to product labeling, varenicline&#x000a0;demonstrates&#x000a0;a high affinity&#x000a0;for&#x000a0;the &#x003b1;<sub>4</sub>&#x003b2;<sub>2</sub> subtypes of nicotinic acetylcholine receptors. Therefore, the efficacy of varenicline in smoking cessation is presumed to result from varenicline&#x02019;s activity at these receptors, where its binding produces partial agonist activity while preventing nicotine binding to these receptors.&#x000a0;This precludes the ability of nicotine to activate &#x003b1;<sub>4</sub>&#x003b2;<sub>2</sub> receptors and stimulate the mesolimbic dopamine system, considered the neuronal mechanism underlying reinforcement and reward a patient experiences upon smoking a cigarette.<xref ref-type="bibr" rid="article-30972.r11">[11]</xref>&#x000a0;Varenicline&#x000a0;reduces the craving and severity of withdrawal syndrome that occurs&#x000a0;during cessation attempts.</p>
        <p>The effectiveness of varenicline nasal spray&#x000a0;for&#x000a0;treating patients with dry eye disease is thought to result from its binding to specific nicotinic acetylcholine (nACh) receptors located on the terminal branches of the trigeminal nerve in the nasal cavity. This binding activates the lacrimal functional unit through the trigeminal parasympathetic pathway, leading to improved production of endogenous tears and basal tear film, which helps alleviate dry eye symptoms.<xref ref-type="bibr" rid="article-30972.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Maximum plasma concentrations of varenicline are typically&#x000a0;achieved within 3 to 4 hours after oral administration. Varenicline exhibits linear pharmacokinetics over the recommended dosing range after single or repeated doses.&#x000a0;</p>
        <p><bold>Distribution:</bold>&#x000a0;Plasma protein binding of varenicline (&#x0003c;20%) is independent of age and renal function of the person.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Varenicline&#x000a0;undergoes minimal metabolism, with 92% of the drug excreted unchanged in the urine. The elimination half-life&#x000a0;of varenicline is around 24 hours.</p>
        <p><bold>Elimination:</bold> Varenicline is primarily eliminated via the kidney through glomerular filtration and active tubular secretion, possibly through the organic cation transporter OCT2.<xref ref-type="bibr" rid="article-30972.r13">[13]</xref></p>
      </sec>
      <sec id="article-30972.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Varenicline is&#x000a0;available as 0.5 mg and 1 mg oral tablets. Patients should take the medication with water to&#x000a0;reduce gastric discomfort. The nasal formulation of varenicline for dry eye contains 0.03&#x000a0;mg per 0.05 mL spray.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Oral</bold>
</p>
        <p><bold>Initiation:</bold> 0.5 mg once daily on days 1 to 3, increased to twice daily on days 4 through 7.&#x000a0;Varenicline therapy&#x000a0;should be initiated 1&#x000a0;week before the target quit date.&#x000a0;Alternatively, the&#x000a0;patients can start varenicline and stop smoking between days 8 and 35.</p>
        <p><bold>Maintenance:</bold> 1 mg twice daily after day 8 for 11 weeks.</p>
        <p><bold>Long-term:</bold> Treatment duration can be up to 6 months or longer in certain patients. Further trials are needed to determine efficacy and outcomes in&#x000a0;patients&#x000a0;receiving&#x000a0;varenicline for over 12 months.</p>
        <p>
<bold>Nasal</bold>
</p>
        <p>Twice daily, with one spray in each nostril. If a dose is missed, continue with the next scheduled dose. Before the first use, the spray should be primed by delivering&#x000a0;7&#x000a0;actuations&#x000a0;into the air. If the spray has not been used for over 5 days, it should be re-primed with 1 actuation. The actuation device should not be shaken.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold>&#x000a0;A maximum dose of 0.5 mg twice daily is recommended for patients with renal impairment (CrCL &#x0003c;30)&#x000a0;or end-stage renal disease (ESRD) on hemodialysis.<xref ref-type="bibr" rid="article-30972.r11">[11]</xref> The manufacturer's label does not specify dosage adjustments for varenicline nasal spray.</p>
        <p><bold>Hepatic impairment:</bold> According to the product labeling, varenicline pharmacokinetics should be unaffected in patients with hepatic impairment due to the lack of significant hepatic metabolism. The manufacturer's label does not specify dosage adjustments for varenicline nasal spray.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Smoking during pregnancy can cause an increased risk of orofacial clefts, premature rupture of membranes, placenta previa, placental abruption, fetal growth restriction, low birth weight, stillbirth, preterm delivery, shortened gestation, reduction of lung function in infants, neonatal death, and sudden infant death syndrome. Clinicians should screen all pregnant&#x000a0;women for nicotine use and recommend smoking cessation if positive. The benefit of tobacco smoking cessation for patients who are pregnant is well established. Hence, behavioral interventions are effective and recommended. However, knowledge related to pharmacotherapy interventions in pregnancy is limited and insufficient to make specific recommendations.<xref ref-type="bibr" rid="article-30972.r14">[14]</xref>&#x000a0;A recent study showed that varenicline was almost&#x000a0;3 times more effective than nicotine patches&#x000a0;in helping pregnant women quit smoking.<xref ref-type="bibr" rid="article-30972.r15">[15]</xref>&#x000a0;Data on varenicline nasal spray use&#x000a0;during pregnancy are lacking; animal studies indicate no malformations at clinical doses.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Varenicline is a partial nicotine agonist used to assist smoking cessation. However, based on animal data on nicotine, varenicline may interfere with infant lung development;&#x000a0;it is not recommended&#x000a0;for nursing mothers.&#x000a0;Given the lack of&#x000a0;data&#x000a0;regarding&#x000a0;varenicline therapy while breastfeeding, other smoking cessation modalities may be preferred. If a mother chooses to breastfeed while using varenicline, clinicians should monitor her infant for seizures and excessive vomiting.<xref ref-type="bibr" rid="article-30972.r10">[10]</xref>&#x000a0;Animal studies indicate varenicline is present in rat milk, but this may not reflect human levels. The risk to infants from varenicline nasal spray during lactation is unclear, so the benefits of breastfeeding should be weighed against the mother's need for the medication.</p>
        <p><bold>Pediatric patients:</bold> Varenicline is not approved for use in patients aged 16 or younger&#x000a0;as its efficacy and safety have not been established in these patients.</p>
        <p><bold>Older patients:</bold> No significant differences in safety or effectiveness&#x000a0;have been&#x000a0;observed in older adults receiving varenicline. Monitoring renal function is advised for older patients due to the increased risk of adverse reactions in&#x000a0;patients with impaired renal function. However, no dosage adjustment is recommended for older patients. No overall differences in safety or effectiveness have been observed between older and younger patients using varenicline nasal spray.</p>
      </sec>
      <sec id="article-30972.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse&#x000a0;reactions associated with&#x000a0;varenicline therapy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Abnormal dreams</p>
          </list-item>
          <list-item>
            <p>Headaches</p>
          </list-item>
        </list>
        <p>Clinicians can mitigate nausea by starting at lower doses and up-titrating the dose as tolerated. Patients also complain of disturbed sleep, sleepwalking, agitation, drowsiness, and constipation.<xref ref-type="bibr" rid="article-30972.r11">[11]</xref>&#x000a0;Varenicline&#x000a0;is also associated with&#x000a0;skin&#x000a0;conditions, including&#x000a0;Stevens-Johnson&#x000a0;syndrome, erythema multiforme, and photosensitivity.<xref ref-type="bibr" rid="article-30972.r16">[16]</xref>&#x000a0;Varenicline can cause renal failure and kidney stones.&#x000a0;Patients taking varenicline should&#x000a0;be monitored for abdominal symptoms of pancreatitis.<xref ref-type="bibr" rid="article-30972.r17">[17]</xref>&#x000a0;Drug-induced reversible cerebral vasoconstriction syndrome has been observed in patients receiving varenicline.<xref ref-type="bibr" rid="article-30972.r18">[18]</xref></p>
        <p>Nasal varenicline is associated with&#x000a0;sneezing, nasal irritation, coughing, and throat irritation.<xref ref-type="bibr" rid="article-30972.r19">[19]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Physiological changes during smoking cessation may affect the pharmacokinetics or pharmacodynamics of certain drugs. Dosage adjustments may be necessary for patients receiving warfarin, theophylline,&#x000a0;or insulin.</p>
        <p>The safety&#x000a0;associated with the co-administration of&#x000a0;bupropion and varenicline has not been established.</p>
      </sec>
      <sec id="article-30972.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Varenicline is contraindicated for patients with a known history of serious hypersensitivity reactions or severe cutaneous adverse drug reactions.<xref ref-type="bibr" rid="article-30972.r16">[16]</xref><xref ref-type="bibr" rid="article-30972.r20">[20]</xref>&#x000a0;Based on the information available, there are no absolute contraindications for the nasal administration of varenicline.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There is an FDA-mandated warning for patients with severe psychiatric symptoms, including suicidal ideation, as these outcomes have been reported in patients receiving varenicline. Patients&#x000a0;receiving varenicline should&#x000a0;be closely monitored for&#x000a0;these behavioral symptoms. Psychiatric illness is not a contraindication for varenicline; however, clinicians should monitor&#x000a0;patients for further deterioration.&#x000a0;Patients exhibiting worsening psychiatric behaviors or suicidal ideation should promptly stop varenicline therapy.<xref ref-type="bibr" rid="article-30972.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Severe hypersensitivity reactions or skin reactions to varenicline may occur, and patients&#x000a0;with Stevens-Johnson&#x000a0;syndrome or erythema multiforme should not take varenicline.<xref ref-type="bibr" rid="article-30972.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with a history of renal impairment, psychiatric disorder, or seizure disorder should be monitored closely.</p>
          </list-item>
          <list-item>
            <p>Cases of somnambulism and nightmares have been documented.<xref ref-type="bibr" rid="article-30972.r21">[21]</xref><xref ref-type="bibr" rid="article-30972.r22">[22]</xref>&#x000a0;Patients&#x000a0;should notify their&#x000a0;provider if they experience somnambulism.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30972.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving varenicline should be&#x000a0;monitored using the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Varenicline is excreted renally; monitoring renal function is crucial.&#x000a0;Before initiating a patient on varenicline, the clinician should obtain a baseline creatinine.<xref ref-type="bibr" rid="article-30972.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Patients on varenicline require close monitoring for signs or symptoms of depression, agitation, behavior changes, skin reactions, or suicidal ideation.</p>
          </list-item>
          <list-item>
            <p>Smoking during pregnancy is widespread and poses a significant public health issue. Varenicline and other newer pharmacologic agents have not been studied well and generally&#x000a0;are not used to promote cessation during pregnancy. Because varenicline is a relatively new drug on the market, few studies have shown strong evidence for either significant positive or negative outcomes associated with the gestational use of varenicline. Currently,&#x000a0;controlled studies have shown no evidence of an increased risk of spontaneous abortion, major congenital malformation, or intrauterine death. Due to limited efficacy and pregnancy safety data, varenicline is not a standard recommendation as a smoking cessation aid for pregnant women. Further studies are necessary for this topic. If a patient has been exposed to varenicline inadvertently during the first trimester, the recommendation is to perform a detailed fetal anomaly scan.<xref ref-type="bibr" rid="article-30972.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Clinicians can monitor abstinence&#x000a0;evaluated by self-report and exhaled carbon monoxide verification.<xref ref-type="bibr" rid="article-30972.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30972.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Evaluation of prolonged exposure to varenicline&#x000a0;in adults has not revealed any alteration of hematological, biochemical, and anatomicopathological parameters.<xref ref-type="bibr" rid="article-30972.r25">[25]</xref>&#x000a0;High doses of varenicline, whether ingested intentionally or accidentally, can result in several symptoms. One notable effect is spontaneous vomiting, likely due to the drug's action on gastrointestinal 5-HT3 receptors. Additionally, transient blood pressure and heart rate increases may occur.<xref ref-type="bibr" rid="article-30972.r25">[25]</xref><xref ref-type="bibr" rid="article-30972.r26">[26]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>If there are serious adverse effects, including psychiatric conditions or skin hypersensitivity reaction, discontinue varenicline immediately. Varenicline therapy can be stopped abruptly with no adverse effects, and there is no need for a taper. There are currently&#x000a0;no antidotes to varenicline. Varenicline is removed by dialysis in patients with end-stage renal disease; however, there is no experience in dialysis following an overdose.<xref ref-type="bibr" rid="article-30972.r24">[24]</xref></p>
      </sec>
      <sec id="article-30972.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Therapy with varenicline requires an interprofessional healthcare team approach to optimize the chance of success and minimize the adverse effect profile. This interprofessional team includes clinicians, nurses, and pharmacists, all collaborating their efforts and exercising open communication so that every team member operates from the same information. Since smoking cessation improves almost all aspects of health, the team needs to create an environment for the greatest patient success.</p>
        <p>Smoking remains a significant public health problem, and despite decades of research, there is no definitive solution to help people quit this social habit. Many drugs are on the market to help people quit smoking, but none works consistently, and relapse rates are high. Because smokers can present&#x000a0;with various medical disorders, the onus is on healthcare workers to educate them on the dangers of smoking. Varenicline is a relatively new drug on the market, and data indicates that it can help people quit smoking in the short term; however, the patient also has to be provided with psychosocial support at the same time.<xref ref-type="bibr" rid="article-30972.r27">[27]</xref><xref ref-type="bibr" rid="article-30972.r28">[28]</xref>&#x000a0;According to a systematic review, hospitalized patients who receive smoking cessation counseling during and after hospitalization have higher quit rates than those with no intervention. Initiating varenicline while the patient is in the hospital is a reasonable strategy.<xref ref-type="bibr" rid="article-30972.r29">[29]</xref>&#x000a0;An interprofessional team approach and communication among clinicians, psychiatrists, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes&#x000a0;related&#x000a0;to varenicline therapy.</p>
      </sec>
      <sec id="article-30972.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30972&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30972">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30972/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30972">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30972.s11">
        <title>References</title>
        <ref id="article-30972.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cinciripini</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Minnix</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Versace</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wetter</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Shete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karam-Hage</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use.</article-title>
            <source>Addiction</source>
            <year>2018</year>
            <month>Apr</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29679432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozinoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>793</fpage>
            <page-range>793-804</page-range>
            <pub-id pub-id-type="pmid">30092681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalkhoran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benowitz</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Rigotti</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Treatment of Tobacco&#x000a0;Use: JACC Health Promotion Series.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>28</day>
            <volume>72</volume>
            <issue>9</issue>
            <fpage>1030</fpage>
            <page-range>1030-1045</page-range>
            <pub-id pub-id-type="pmid">30139432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Panchal</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2023</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-533</page-range>
            <pub-id pub-id-type="pmid">37397838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>E</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis.</article-title>
            <source>J Addict Med</source>
            <string-date>2023 Sep-Oct 01</string-date>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>536</fpage>
            <page-range>536-543</page-range>
            <pub-id pub-id-type="pmid">37788606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ackerson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adeoye</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Bambakidis</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Biller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demaerschalk</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hoh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jauch</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kidwell</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Leslie-Mazwi</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Southerland</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Tirschwell</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</article-title>
            <source>Stroke</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>12</issue>
            <fpage>e344</fpage>
            <page-range>e344-e418</page-range>
            <pub-id pub-id-type="pmid">31662037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Evers-Casey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evins</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Eakin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Fathi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fennig</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Folan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galiatsatos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gogineni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kantrow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kathuria</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lamphere</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neptune</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pakhale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prezant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>DPL</given-names>
              </name>
              <name>
                <surname>Toll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Upson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cruz-Lopes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fulone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pavalagantharajah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2020</year>
            <month>Jul</month>
            <day>15</day>
            <volume>202</volume>
            <issue>2</issue>
            <fpage>e5</fpage>
            <page-range>e5-e31</page-range>
            <pub-id pub-id-type="pmid">32663106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauswirth</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kabat</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hemphill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Somaiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hendrix</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.</article-title>
            <source>J Comp Eff Res</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e220215</fpage>
            <pub-id pub-id-type="pmid">37096956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballesteros-S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borroni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De-Hita-Cantalejo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Gonz&#x000e1;lez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sanchez-Gomez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rocha-de-Lossada</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Gonz&#x000e1;lez</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review.</article-title>
            <source>Cont Lens Anterior Eye</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>102097</fpage>
            <pub-id pub-id-type="pmid">38065797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Varenicline</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarthy</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Versella</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Quitting Failure and Success With and Without Using Medication: Latent Classes of Abstinence and Adherence to Nicotine Monotherapy, Combination Therapy, and Varenicline.</article-title>
            <source>Nicotine Tob Res</source>
            <year>2019</year>
            <month>Oct</month>
            <day>26</day>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1488</fpage>
            <page-range>1488-1495</page-range>
            <pub-id pub-id-type="pmid">30107419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epitropoulos</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Daya</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Matossian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kabat</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Blemker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Striffler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hendrix</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Macsai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2022</year>
            <volume>16</volume>
            <fpage>3405</fpage>
            <page-range>3405-3413</page-range>
            <pub-id pub-id-type="pmid">36249445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jordan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>ZX</given-names>
              </name>
            </person-group>
            <article-title>Discovery and development of varenicline for smoking cessation.</article-title>
            <source>Expert Opin Drug Discov</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>671</fpage>
            <page-range>671-683</page-range>
            <pub-id pub-id-type="pmid">29587555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Krist</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cabana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Doubeni</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kubik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pbert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stevermer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Mar</month>
            <day>09</day>
            <volume>325</volume>
            <issue>10</issue>
            <fpage>962</fpage>
            <page-range>962-970</page-range>
            <pub-id pub-id-type="pmid">33687470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>SKY</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Kemp-Casey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preen</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Einarsdottir</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jorm</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Havard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Comparative Effectiveness of Varenicline and Nicotine Patches for Smoking Abstinence During Pregnancy: Evidence From a Population-based Cohort Study.</article-title>
            <source>Nicotine Tob Res</source>
            <year>2021</year>
            <month>Aug</month>
            <day>29</day>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>1664</fpage>
            <page-range>1664-1672</page-range>
            <pub-id pub-id-type="pmid">34398235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zkaya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yazgano&#x0011f;lu</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kutlay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahmudov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Varenicline-induced acute generalized exanthematous pustulosis confirmed by patch testing.</article-title>
            <source>Contact Dermatitis</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-99</page-range>
            <pub-id pub-id-type="pmid">29265452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollema</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>The contribution of agonist and antagonist activities of &#x003b1;4&#x003b2;2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>235</volume>
            <issue>9</issue>
            <fpage>2479</fpage>
            <page-range>2479-2505</page-range>
            <pub-id pub-id-type="pmid">29980822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Favreli&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mah&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veyrac</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neau</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lafay-Chebassier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rault-Pochat</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase<sup>&#x000ae;</sup>.</article-title>
            <source>Cephalalgia</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>3331024241267316</fpage>
            <pub-id pub-id-type="pmid">39127462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zitko</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ladd</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dougherty</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease.</article-title>
            <source>J Pharm Pract</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1448</fpage>
            <page-range>1448-1453</page-range>
            <pub-id pub-id-type="pmid">35703427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seak</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>ZNL</given-names>
              </name>
              <name>
                <surname>Seak</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Seak</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Life-Threatening Angioedema Following Varenicline Administration.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-287</page-range>
            <pub-id pub-id-type="pmid">30925501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Zekarias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caduff-Janosa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Varenicline and abnormal sleep related events.</article-title>
            <source>Sleep</source>
            <year>2015</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>833</fpage>
            <page-range>833-7</page-range>
            <pub-id pub-id-type="pmid">25409105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gwak</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Sleep-related adverse events of smoking cessation drugs: A network meta-analysis of randomized controlled trials.</article-title>
            <source>Psychiatry Res</source>
            <year>2024</year>
            <month>May</month>
            <volume>335</volume>
            <fpage>115874</fpage>
            <pub-id pub-id-type="pmid">38564922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy.</article-title>
            <source>Nicotine Tob Res</source>
            <year>2019</year>
            <month>Jul</month>
            <day>17</day>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>1001</fpage>
            <page-range>1001-1010</page-range>
            <pub-id pub-id-type="pmid">29579233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaccarelli-Magalh&#x000e3;es</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sandini</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>de Abreu</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Sarmiento</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>de Souza Spinosa</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Haematological, Biochemical and Anatomopathological Studies.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-309</page-range>
            <pub-id pub-id-type="pmid">28944993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;rup</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Varenicline poisoning for a suicidal purpose].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2014</year>
            <month>Jun</month>
            <day>02</day>
            <volume>176</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">25352081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollema</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Faessel</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Varenicline overdose in a teenager--a clinical pharmacology perspective.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>605</fpage>
            <pub-id pub-id-type="pmid">19586362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klemperer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Naud</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Study Characteristics Influence the Efficacy of Substance Abuse Treatments: A Meta-analysis of Medications for Smoking Cessation.</article-title>
            <source>Nicotine Tob Res</source>
            <year>2020</year>
            <month>Mar</month>
            <day>16</day>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-323</page-range>
            <pub-id pub-id-type="pmid">30380134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goulden</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk of Bias in Study of Varenicline and Cardiovascular Outcomes.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>198</volume>
            <issue>5</issue>
            <fpage>690</fpage>
            <page-range>690-691</page-range>
            <pub-id pub-id-type="pmid">29708402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30972.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Streck</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rigotti</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Livingstone-Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tindle</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Clair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Munaf&#x000f2;</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sterling-Maisel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hartmann-Boyce</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interventions for smoking cessation in hospitalised patients.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2024</year>
            <month>May</month>
            <day>21</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD001837</fpage>
            <pub-id pub-id-type="pmid">38770804</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
